Global Neuroblastoma Treatment Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Page: 97

Published Date: 01 Jan 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.

According to our (Global Info Research) latest study, the global Neuroblastoma Treatment Drugs market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Neuroblastoma Treatment Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Neuroblastoma Treatment Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Neuroblastoma Treatment Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Neuroblastoma Treatment Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Neuroblastoma Treatment Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neuroblastoma Treatment Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neuroblastoma Treatment Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals and Baxter Healthcare, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation
Neuroblastoma Treatment Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Cyclophosphamide
    Dinutuximab
    Naxitamab
    Doxorubicin Hydrochloride
    Vincristine Sulfate
    Other

Market segment by Application
    Hospital
    Clinic
    Other

Major players covered
    United Therapeutics
    Y-mAbs Therapeutics
    EUSA Pharma
    ANI Pharmaceuticals
    Baxter Healthcare
    Ingenus Pharmaceuticals
    Pfizer
    Hikma Pharmaceuticals
    Teva Pharmaceuticals

Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neuroblastoma Treatment Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Neuroblastoma Treatment Drugs, with price, sales, revenue and global market share of Neuroblastoma Treatment Drugs from 2018 to 2023.
Chapter 3, the Neuroblastoma Treatment Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuroblastoma Treatment Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Neuroblastoma Treatment Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Neuroblastoma Treatment Drugs.
Chapter 14 and 15, to describe Neuroblastoma Treatment Drugs sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Neuroblastoma Treatment Drugs
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Neuroblastoma Treatment Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Cyclophosphamide
        1.3.3 Dinutuximab
        1.3.4 Naxitamab
        1.3.5 Doxorubicin Hydrochloride
        1.3.6 Vincristine Sulfate
        1.3.7 Other
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Neuroblastoma Treatment Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Hospital
        1.4.3 Clinic
        1.4.4 Other
    1.5 Global Neuroblastoma Treatment Drugs Market Size & Forecast
        1.5.1 Global Neuroblastoma Treatment Drugs Consumption Value (2018 & 2022 & 2029)
        1.5.2 Global Neuroblastoma Treatment Drugs Sales Quantity (2018-2029)
        1.5.3 Global Neuroblastoma Treatment Drugs Average Price (2018-2029)

2 Manufacturers Profiles
    2.1 United Therapeutics
        2.1.1 United Therapeutics Details
        2.1.2 United Therapeutics Major Business
        2.1.3 United Therapeutics Neuroblastoma Treatment Drugs Product and Services
        2.1.4 United Therapeutics Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 United Therapeutics Recent Developments/Updates
    2.2 Y-mAbs Therapeutics
        2.2.1 Y-mAbs Therapeutics Details
        2.2.2 Y-mAbs Therapeutics Major Business
        2.2.3 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product and Services
        2.2.4 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Y-mAbs Therapeutics Recent Developments/Updates
    2.3 EUSA Pharma
        2.3.1 EUSA Pharma Details
        2.3.2 EUSA Pharma Major Business
        2.3.3 EUSA Pharma Neuroblastoma Treatment Drugs Product and Services
        2.3.4 EUSA Pharma Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 EUSA Pharma Recent Developments/Updates
    2.4 ANI Pharmaceuticals
        2.4.1 ANI Pharmaceuticals Details
        2.4.2 ANI Pharmaceuticals Major Business
        2.4.3 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
        2.4.4 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 ANI Pharmaceuticals Recent Developments/Updates
    2.5 Baxter Healthcare
        2.5.1 Baxter Healthcare Details
        2.5.2 Baxter Healthcare Major Business
        2.5.3 Baxter Healthcare Neuroblastoma Treatment Drugs Product and Services
        2.5.4 Baxter Healthcare Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Baxter Healthcare Recent Developments/Updates
    2.6 Ingenus Pharmaceuticals
        2.6.1 Ingenus Pharmaceuticals Details
        2.6.2 Ingenus Pharmaceuticals Major Business
        2.6.3 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
        2.6.4 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
    2.7 Pfizer
        2.7.1 Pfizer Details
        2.7.2 Pfizer Major Business
        2.7.3 Pfizer Neuroblastoma Treatment Drugs Product and Services
        2.7.4 Pfizer Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 Pfizer Recent Developments/Updates
    2.8 Hikma Pharmaceuticals
        2.8.1 Hikma Pharmaceuticals Details
        2.8.2 Hikma Pharmaceuticals Major Business
        2.8.3 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
        2.8.4 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 Hikma Pharmaceuticals Recent Developments/Updates
    2.9 Teva Pharmaceuticals
        2.9.1 Teva Pharmaceuticals Details
        2.9.2 Teva Pharmaceuticals Major Business
        2.9.3 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
        2.9.4 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.9.5 Teva Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Neuroblastoma Treatment Drugs by Manufacturer
    3.1 Global Neuroblastoma Treatment Drugs Sales Quantity by Manufacturer (2018-2023)
    3.2 Global Neuroblastoma Treatment Drugs Revenue by Manufacturer (2018-2023)
    3.3 Global Neuroblastoma Treatment Drugs Average Price by Manufacturer (2018-2023)
    3.4 Market Share Analysis (2022)
        3.4.1 Producer Shipments of Neuroblastoma Treatment Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
        3.4.2 Top 3 Neuroblastoma Treatment Drugs Manufacturer Market Share in 2022
        3.4.2 Top 6 Neuroblastoma Treatment Drugs Manufacturer Market Share in 2022
    3.5 Neuroblastoma Treatment Drugs Market: Overall Company Footprint Analysis
        3.5.1 Neuroblastoma Treatment Drugs Market: Region Footprint
        3.5.2 Neuroblastoma Treatment Drugs Market: Company Product Type Footprint
        3.5.3 Neuroblastoma Treatment Drugs Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Neuroblastoma Treatment Drugs Market Size by Region
        4.1.1 Global Neuroblastoma Treatment Drugs Sales Quantity by Region (2018-2029)
        4.1.2 Global Neuroblastoma Treatment Drugs Consumption Value by Region (2018-2029)
        4.1.3 Global Neuroblastoma Treatment Drugs Average Price by Region (2018-2029)
    4.2 North America Neuroblastoma Treatment Drugs Consumption Value (2018-2029)
    4.3 Europe Neuroblastoma Treatment Drugs Consumption Value (2018-2029)
    4.4 Asia-Pacific Neuroblastoma Treatment Drugs Consumption Value (2018-2029)
    4.5 South America Neuroblastoma Treatment Drugs Consumption Value (2018-2029)
    4.6 Middle East and Africa Neuroblastoma Treatment Drugs Consumption Value (2018-2029)

5 Market Segment by Type
    5.1 Global Neuroblastoma Treatment Drugs Sales Quantity by Type (2018-2029)
    5.2 Global Neuroblastoma Treatment Drugs Consumption Value by Type (2018-2029)
    5.3 Global Neuroblastoma Treatment Drugs Average Price by Type (2018-2029)

6 Market Segment by Application
    6.1 Global Neuroblastoma Treatment Drugs Sales Quantity by Application (2018-2029)
    6.2 Global Neuroblastoma Treatment Drugs Consumption Value by Application (2018-2029)
    6.3 Global Neuroblastoma Treatment Drugs Average Price by Application (2018-2029)

7 North America
    7.1 North America Neuroblastoma Treatment Drugs Sales Quantity by Type (2018-2029)
    7.2 North America Neuroblastoma Treatment Drugs Sales Quantity by Application (2018-2029)
    7.3 North America Neuroblastoma Treatment Drugs Market Size by Country
        7.3.1 North America Neuroblastoma Treatment Drugs Sales Quantity by Country (2018-2029)
        7.3.2 North America Neuroblastoma Treatment Drugs Consumption Value by Country (2018-2029)
        7.3.3 United States Market Size and Forecast (2018-2029)
        7.3.4 Canada Market Size and Forecast (2018-2029)
        7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe
    8.1 Europe Neuroblastoma Treatment Drugs Sales Quantity by Type (2018-2029)
    8.2 Europe Neuroblastoma Treatment Drugs Sales Quantity by Application (2018-2029)
    8.3 Europe Neuroblastoma Treatment Drugs Market Size by Country
        8.3.1 Europe Neuroblastoma Treatment Drugs Sales Quantity by Country (2018-2029)
        8.3.2 Europe Neuroblastoma Treatment Drugs Consumption Value by Country (2018-2029)
        8.3.3 Germany Market Size and Forecast (2018-2029)
        8.3.4 France Market Size and Forecast (2018-2029)
        8.3.5 United Kingdom Market Size and Forecast (2018-2029)
        8.3.6 Russia Market Size and Forecast (2018-2029)
        8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific
    9.1 Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Type (2018-2029)
    9.2 Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Application (2018-2029)
    9.3 Asia-Pacific Neuroblastoma Treatment Drugs Market Size by Region
        9.3.1 Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Region (2018-2029)
        9.3.2 Asia-Pacific Neuroblastoma Treatment Drugs Consumption Value by Region (2018-2029)
        9.3.3 China Market Size and Forecast (2018-2029)
        9.3.4 Japan Market Size and Forecast (2018-2029)
        9.3.5 Korea Market Size and Forecast (2018-2029)
        9.3.6 India Market Size and Forecast (2018-2029)
        9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
        9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America
    10.1 South America Neuroblastoma Treatment Drugs Sales Quantity by Type (2018-2029)
    10.2 South America Neuroblastoma Treatment Drugs Sales Quantity by Application (2018-2029)
    10.3 South America Neuroblastoma Treatment Drugs Market Size by Country
        10.3.1 South America Neuroblastoma Treatment Drugs Sales Quantity by Country (2018-2029)
        10.3.2 South America Neuroblastoma Treatment Drugs Consumption Value by Country (2018-2029)
        10.3.3 Brazil Market Size and Forecast (2018-2029)
        10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa
    11.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Type (2018-2029)
    11.2 Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Application (2018-2029)
    11.3 Middle East & Africa Neuroblastoma Treatment Drugs Market Size by Country
        11.3.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Country (2018-2029)
        11.3.2 Middle East & Africa Neuroblastoma Treatment Drugs Consumption Value by Country (2018-2029)
        11.3.3 Turkey Market Size and Forecast (2018-2029)
        11.3.4 Egypt Market Size and Forecast (2018-2029)
        11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
        11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics
    12.1 Neuroblastoma Treatment Drugs Market Drivers
    12.2 Neuroblastoma Treatment Drugs Market Restraints
    12.3 Neuroblastoma Treatment Drugs Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry
    12.5 Influence of COVID-19 and Russia-Ukraine War
        12.5.1 Influence of COVID-19
        12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain
    13.1 Raw Material of Neuroblastoma Treatment Drugs and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Neuroblastoma Treatment Drugs
    13.3 Neuroblastoma Treatment Drugs Production Process
    13.4 Neuroblastoma Treatment Drugs Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Neuroblastoma Treatment Drugs Typical Distributors
    14.3 Neuroblastoma Treatment Drugs Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Neuroblastoma Treatment Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Neuroblastoma Treatment Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. United Therapeutics Basic Information, Manufacturing Base and Competitors
    Table 4. United Therapeutics Major Business
    Table 5. United Therapeutics Neuroblastoma Treatment Drugs Product and Services
    Table 6. United Therapeutics Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 7. United Therapeutics Recent Developments/Updates
    Table 8. Y-mAbs Therapeutics Basic Information, Manufacturing Base and Competitors
    Table 9. Y-mAbs Therapeutics Major Business
    Table 10. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product and Services
    Table 11. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 12. Y-mAbs Therapeutics Recent Developments/Updates
    Table 13. EUSA Pharma Basic Information, Manufacturing Base and Competitors
    Table 14. EUSA Pharma Major Business
    Table 15. EUSA Pharma Neuroblastoma Treatment Drugs Product and Services
    Table 16. EUSA Pharma Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 17. EUSA Pharma Recent Developments/Updates
    Table 18. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 19. ANI Pharmaceuticals Major Business
    Table 20. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
    Table 21. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 22. ANI Pharmaceuticals Recent Developments/Updates
    Table 23. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
    Table 24. Baxter Healthcare Major Business
    Table 25. Baxter Healthcare Neuroblastoma Treatment Drugs Product and Services
    Table 26. Baxter Healthcare Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 27. Baxter Healthcare Recent Developments/Updates
    Table 28. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 29. Ingenus Pharmaceuticals Major Business
    Table 30. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
    Table 31. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 32. Ingenus Pharmaceuticals Recent Developments/Updates
    Table 33. Pfizer Basic Information, Manufacturing Base and Competitors
    Table 34. Pfizer Major Business
    Table 35. Pfizer Neuroblastoma Treatment Drugs Product and Services
    Table 36. Pfizer Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 37. Pfizer Recent Developments/Updates
    Table 38. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 39. Hikma Pharmaceuticals Major Business
    Table 40. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
    Table 41. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 42. Hikma Pharmaceuticals Recent Developments/Updates
    Table 43. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 44. Teva Pharmaceuticals Major Business
    Table 45. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
    Table 46. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 47. Teva Pharmaceuticals Recent Developments/Updates
    Table 48. Global Neuroblastoma Treatment Drugs Sales Quantity by Manufacturer (2018-2023) & (K Units)
    Table 49. Global Neuroblastoma Treatment Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
    Table 50. Global Neuroblastoma Treatment Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
    Table 51. Market Position of Manufacturers in Neuroblastoma Treatment Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
    Table 52. Head Office and Neuroblastoma Treatment Drugs Production Site of Key Manufacturer
    Table 53. Neuroblastoma Treatment Drugs Market: Company Product Type Footprint
    Table 54. Neuroblastoma Treatment Drugs Market: Company Product Application Footprint
    Table 55. Neuroblastoma Treatment Drugs New Market Entrants and Barriers to Market Entry
    Table 56. Neuroblastoma Treatment Drugs Mergers, Acquisition, Agreements, and Collaborations
    Table 57. Global Neuroblastoma Treatment Drugs Sales Quantity by Region (2018-2023) & (K Units)
    Table 58. Global Neuroblastoma Treatment Drugs Sales Quantity by Region (2024-2029) & (K Units)
    Table 59. Global Neuroblastoma Treatment Drugs Consumption Value by Region (2018-2023) & (USD Million)
    Table 60. Global Neuroblastoma Treatment Drugs Consumption Value by Region (2024-2029) & (USD Million)
    Table 61. Global Neuroblastoma Treatment Drugs Average Price by Region (2018-2023) & (US$/Unit)
    Table 62. Global Neuroblastoma Treatment Drugs Average Price by Region (2024-2029) & (US$/Unit)
    Table 63. Global Neuroblastoma Treatment Drugs Sales Quantity by Type (2018-2023) & (K Units)
    Table 64. Global Neuroblastoma Treatment Drugs Sales Quantity by Type (2024-2029) & (K Units)
    Table 65. Global Neuroblastoma Treatment Drugs Consumption Value by Type (2018-2023) & (USD Million)
    Table 66. Global Neuroblastoma Treatment Drugs Consumption Value by Type (2024-2029) & (USD Million)
    Table 67. Global Neuroblastoma Treatment Drugs Average Price by Type (2018-2023) & (US$/Unit)
    Table 68. Global Neuroblastoma Treatment Drugs Average Price by Type (2024-2029) & (US$/Unit)
    Table 69. Global Neuroblastoma Treatment Drugs Sales Quantity by Application (2018-2023) & (K Units)
    Table 70. Global Neuroblastoma Treatment Drugs Sales Quantity by Application (2024-2029) & (K Units)
    Table 71. Global Neuroblastoma Treatment Drugs Consumption Value by Application (2018-2023) & (USD Million)
    Table 72. Global Neuroblastoma Treatment Drugs Consumption Value by Application (2024-2029) & (USD Million)
    Table 73. Global Neuroblastoma Treatment Drugs Average Price by Application (2018-2023) & (US$/Unit)
    Table 74. Global Neuroblastoma Treatment Drugs Average Price by Application (2024-2029) & (US$/Unit)
    Table 75. North America Neuroblastoma Treatment Drugs Sales Quantity by Type (2018-2023) & (K Units)
    Table 76. North America Neuroblastoma Treatment Drugs Sales Quantity by Type (2024-2029) & (K Units)
    Table 77. North America Neuroblastoma Treatment Drugs Sales Quantity by Application (2018-2023) & (K Units)
    Table 78. North America Neuroblastoma Treatment Drugs Sales Quantity by Application (2024-2029) & (K Units)
    Table 79. North America Neuroblastoma Treatment Drugs Sales Quantity by Country (2018-2023) & (K Units)
    Table 80. North America Neuroblastoma Treatment Drugs Sales Quantity by Country (2024-2029) & (K Units)
    Table 81. North America Neuroblastoma Treatment Drugs Consumption Value by Country (2018-2023) & (USD Million)
    Table 82. North America Neuroblastoma Treatment Drugs Consumption Value by Country (2024-2029) & (USD Million)
    Table 83. Europe Neuroblastoma Treatment Drugs Sales Quantity by Type (2018-2023) & (K Units)
    Table 84. Europe Neuroblastoma Treatment Drugs Sales Quantity by Type (2024-2029) & (K Units)
    Table 85. Europe Neuroblastoma Treatment Drugs Sales Quantity by Application (2018-2023) & (K Units)
    Table 86. Europe Neuroblastoma Treatment Drugs Sales Quantity by Application (2024-2029) & (K Units)
    Table 87. Europe Neuroblastoma Treatment Drugs Sales Quantity by Country (2018-2023) & (K Units)
    Table 88. Europe Neuroblastoma Treatment Drugs Sales Quantity by Country (2024-2029) & (K Units)
    Table 89. Europe Neuroblastoma Treatment Drugs Consumption Value by Country (2018-2023) & (USD Million)
    Table 90. Europe Neuroblastoma Treatment Drugs Consumption Value by Country (2024-2029) & (USD Million)
    Table 91. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Type (2018-2023) & (K Units)
    Table 92. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Type (2024-2029) & (K Units)
    Table 93. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Application (2018-2023) & (K Units)
    Table 94. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Application (2024-2029) & (K Units)
    Table 95. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Region (2018-2023) & (K Units)
    Table 96. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Region (2024-2029) & (K Units)
    Table 97. Asia-Pacific Neuroblastoma Treatment Drugs Consumption Value by Region (2018-2023) & (USD Million)
    Table 98. Asia-Pacific Neuroblastoma Treatment Drugs Consumption Value by Region (2024-2029) & (USD Million)
    Table 99. South America Neuroblastoma Treatment Drugs Sales Quantity by Type (2018-2023) & (K Units)
    Table 100. South America Neuroblastoma Treatment Drugs Sales Quantity by Type (2024-2029) & (K Units)
    Table 101. South America Neuroblastoma Treatment Drugs Sales Quantity by Application (2018-2023) & (K Units)
    Table 102. South America Neuroblastoma Treatment Drugs Sales Quantity by Application (2024-2029) & (K Units)
    Table 103. South America Neuroblastoma Treatment Drugs Sales Quantity by Country (2018-2023) & (K Units)
    Table 104. South America Neuroblastoma Treatment Drugs Sales Quantity by Country (2024-2029) & (K Units)
    Table 105. South America Neuroblastoma Treatment Drugs Consumption Value by Country (2018-2023) & (USD Million)
    Table 106. South America Neuroblastoma Treatment Drugs Consumption Value by Country (2024-2029) & (USD Million)
    Table 107. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Type (2018-2023) & (K Units)
    Table 108. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Type (2024-2029) & (K Units)
    Table 109. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Application (2018-2023) & (K Units)
    Table 110. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Application (2024-2029) & (K Units)
    Table 111. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Region (2018-2023) & (K Units)
    Table 112. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Region (2024-2029) & (K Units)
    Table 113. Middle East & Africa Neuroblastoma Treatment Drugs Consumption Value by Region (2018-2023) & (USD Million)
    Table 114. Middle East & Africa Neuroblastoma Treatment Drugs Consumption Value by Region (2024-2029) & (USD Million)
    Table 115. Neuroblastoma Treatment Drugs Raw Material
    Table 116. Key Manufacturers of Neuroblastoma Treatment Drugs Raw Materials
    Table 117. Neuroblastoma Treatment Drugs Typical Distributors
    Table 118. Neuroblastoma Treatment Drugs Typical Customers
List of Figures
    Figure 1. Neuroblastoma Treatment Drugs Picture
    Figure 2. Global Neuroblastoma Treatment Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Neuroblastoma Treatment Drugs Consumption Value Market Share by Type in 2022
    Figure 4. Cyclophosphamide Examples
    Figure 5. Dinutuximab Examples
    Figure 6. Naxitamab Examples
    Figure 7. Doxorubicin Hydrochloride Examples
    Figure 8. Vincristine Sulfate Examples
    Figure 9. Other Examples
    Figure 10. Global Neuroblastoma Treatment Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 11. Global Neuroblastoma Treatment Drugs Consumption Value Market Share by Application in 2022
    Figure 12. Hospital Examples
    Figure 13. Clinic Examples
    Figure 14. Other Examples
    Figure 15. Global Neuroblastoma Treatment Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 16. Global Neuroblastoma Treatment Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 17. Global Neuroblastoma Treatment Drugs Sales Quantity (2018-2029) & (K Units)
    Figure 18. Global Neuroblastoma Treatment Drugs Average Price (2018-2029) & (US$/Unit)
    Figure 19. Global Neuroblastoma Treatment Drugs Sales Quantity Market Share by Manufacturer in 2022
    Figure 20. Global Neuroblastoma Treatment Drugs Consumption Value Market Share by Manufacturer in 2022
    Figure 21. Producer Shipments of Neuroblastoma Treatment Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
    Figure 22. Top 3 Neuroblastoma Treatment Drugs Manufacturer (Consumption Value) Market Share in 2022
    Figure 23. Top 6 Neuroblastoma Treatment Drugs Manufacturer (Consumption Value) Market Share in 2022
    Figure 24. Global Neuroblastoma Treatment Drugs Sales Quantity Market Share by Region (2018-2029)
    Figure 25. Global Neuroblastoma Treatment Drugs Consumption Value Market Share by Region (2018-2029)
    Figure 26. North America Neuroblastoma Treatment Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 27. Europe Neuroblastoma Treatment Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 28. Asia-Pacific Neuroblastoma Treatment Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 29. South America Neuroblastoma Treatment Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 30. Middle East & Africa Neuroblastoma Treatment Drugs Consumption Value (2018-2029) & (USD Million)
    Figure 31. Global Neuroblastoma Treatment Drugs Sales Quantity Market Share by Type (2018-2029)
    Figure 32. Global Neuroblastoma Treatment Drugs Consumption Value Market Share by Type (2018-2029)
    Figure 33. Global Neuroblastoma Treatment Drugs Average Price by Type (2018-2029) & (US$/Unit)
    Figure 34. Global Neuroblastoma Treatment Drugs Sales Quantity Market Share by Application (2018-2029)
    Figure 35. Global Neuroblastoma Treatment Drugs Consumption Value Market Share by Application (2018-2029)
    Figure 36. Global Neuroblastoma Treatment Drugs Average Price by Application (2018-2029) & (US$/Unit)
    Figure 37. North America Neuroblastoma Treatment Drugs Sales Quantity Market Share by Type (2018-2029)
    Figure 38. North America Neuroblastoma Treatment Drugs Sales Quantity Market Share by Application (2018-2029)
    Figure 39. North America Neuroblastoma Treatment Drugs Sales Quantity Market Share by Country (2018-2029)
    Figure 40. North America Neuroblastoma Treatment Drugs Consumption Value Market Share by Country (2018-2029)
    Figure 41. United States Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 42. Canada Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 43. Mexico Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 44. Europe Neuroblastoma Treatment Drugs Sales Quantity Market Share by Type (2018-2029)
    Figure 45. Europe Neuroblastoma Treatment Drugs Sales Quantity Market Share by Application (2018-2029)
    Figure 46. Europe Neuroblastoma Treatment Drugs Sales Quantity Market Share by Country (2018-2029)
    Figure 47. Europe Neuroblastoma Treatment Drugs Consumption Value Market Share by Country (2018-2029)
    Figure 48. Germany Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 49. France Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 50. United Kingdom Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 51. Russia Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 52. Italy Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 53. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity Market Share by Type (2018-2029)
    Figure 54. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity Market Share by Application (2018-2029)
    Figure 55. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity Market Share by Region (2018-2029)
    Figure 56. Asia-Pacific Neuroblastoma Treatment Drugs Consumption Value Market Share by Region (2018-2029)
    Figure 57. China Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 58. Japan Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 59. Korea Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 60. India Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 61. Southeast Asia Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 62. Australia Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 63. South America Neuroblastoma Treatment Drugs Sales Quantity Market Share by Type (2018-2029)
    Figure 64. South America Neuroblastoma Treatment Drugs Sales Quantity Market Share by Application (2018-2029)
    Figure 65. South America Neuroblastoma Treatment Drugs Sales Quantity Market Share by Country (2018-2029)
    Figure 66. South America Neuroblastoma Treatment Drugs Consumption Value Market Share by Country (2018-2029)
    Figure 67. Brazil Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 68. Argentina Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 69. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity Market Share by Type (2018-2029)
    Figure 70. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity Market Share by Application (2018-2029)
    Figure 71. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity Market Share by Region (2018-2029)
    Figure 72. Middle East & Africa Neuroblastoma Treatment Drugs Consumption Value Market Share by Region (2018-2029)
    Figure 73. Turkey Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 74. Egypt Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 75. Saudi Arabia Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 76. South Africa Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 77. Neuroblastoma Treatment Drugs Market Drivers
    Figure 78. Neuroblastoma Treatment Drugs Market Restraints
    Figure 79. Neuroblastoma Treatment Drugs Market Trends
    Figure 80. Porters Five Forces Analysis
    Figure 81. Manufacturing Cost Structure Analysis of Neuroblastoma Treatment Drugs in 2022
    Figure 82. Manufacturing Process Analysis of Neuroblastoma Treatment Drugs
    Figure 83. Neuroblastoma Treatment Drugs Industrial Chain
    Figure 84. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 85. Direct Channel Pros & Cons
    Figure 86. Indirect Channel Pros & Cons
    Figure 87. Methodology
    Figure 88. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals

Related Reports

Global Neuroblastoma Treatment Drugs Supply, Demand and Key Producers, 2023-2029

Global Neuroblastoma Treatment Drugs Supply, Demand and Key Producers, 2023-2029

date 20 Feb 2023

date Pharma & Healthcare

The global Neuroblastoma Treatment Drugs market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Neuroblastoma Treatment Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Neuroblastoma Treatment Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 09 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Neuroblastoma Treatment Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Product Tags

Neuroblastoma Treatment Drugs

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>